Baldo Scassellati Sforzolini, MD, PhD, MBA: Expanding Nemolizumab’s Access
Scassellati Sforzolini discusses the significance of Galderma’s nemolizumab receiving 4 additional filing acceptances for prurigo nodularis and atopic dermatitis.
Cracking the Code on Chronic Hand Eczema
Day 2 Recap: Fall Clinical Dermatology Conference for PAs and NPs 2025
Del Rosso Highlights Next-Gen Treatments
Gene Expression Profiling as an Emerging Tool in Skin Cancer Management